Jennifer Ho, MD, of The University of Texas MD Anderson Cancer, discusses study results on the use of intensity-modulated proton therapy, which can provide durable local control with minimal toxicity in patients who can have extended survivals; the data also suggest that higher doses may improve outcomes (Abstract 5).
Douglas E. Wood, MD, of the University of Washington, discusses the importance of broad access to and education about lung cancer screening—now approved for people at high risk for the disease—and the need for expanded criteria for screening eligibility.
Tracey L. Evans, MD, of the University of Pennsylvania, discusses the data supporting use of chemotherapy with radiation in locally advanced non–small cell lung cancer, targeted treatments and immunotherapy, and some of the controversies now debated.
Boris Sepesi, MD, of The University of Texas MD Anderson Cancer Center, discusses immune cells within tumors and the potential role for checkpoint inhibitor therapy in the neoadjuvant setting of locally advanced lung cancer (Abstract 7).
Martin J. Edelman, MD, of Fox Chase Cancer Center, discusses study findings from a phase III study of celecoxib in addition to standard chemotherapy for advanced non–small cell lung cancer with COX-2 overexpression (Abstract 2).
Kamran Ahmed, MD, of the H. Lee Moffitt Cancer Center and Research Institute, discusses results from a small study of pneumonitis in patients who received thoracic radiotherapy within 6 months of anti–PD-1 therapy, anti–PD-L1 therapy, anti–CTLA-4 therapy, or some combination of these drugs (Abstract 10).
